BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and ...

Larimar Therapeutics Inc (LRMR) stock saw a modest uptick, ending the day at $7.14 which represents a slight increase of $0.29 or 4.23% from the prior close of $6.85. The stock opened at $7.08 and ...

Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

Robert W. Baird has recently initiated Larimar Therapeutics Inc (LRMR) stock to Outperform rating, as announced on September 4, 2024, according to Finviz. Earlier, on April 3, 2024, Leerink Partners ...